Allergan Q3 Earnings Deck

Q3 2016
RESULTS
Focused, Sustainable Growth
Pharma Leader
ALLERGAN CAUTIONARY STATEMENT REGARDING

FORWARD-LOOKING STATEMENTS
This communication includes statements that refer to estimated or anticipated future events and are forwardlooking statements. We have based our forwardlooking statements on managements beliefs and assumptions based on information
available to our management at the time these statements are made. Such forwardlooking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of this filing. These include, but
are not limited to, our beliefs about future revenue and expense levels and growth rates, prospects related to our strategic initiatives and business strategies, including the integration of, and synergies associated with, strategic acquisitions, express or
implied assumptions about government regulatory action or inaction, anticipated product approvals and launches, business initiatives and product development activities, assessments related to clinical trial results, product performance and
competitive environment, and anticipated financial performance. Without limiting the generality of the foregoing, words such as may, will, expect, believe, anticipate, plan, intend, could, would, should, estimate, continue, or pursue,
or the negative or other variations thereof or comparable terminology, are intended to identify forwardlooking statements. The statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are
difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of which are beyond our control. In addition, certain important factors may affect our actual operating results and could
cause such results to differ materially from those expressed or implied by forwardlooking statements. These factors include, among others the inherent uncertainty associated with financial projections; the anticipated size of the markets and continued
demand for Allergans existing products; Allergans ability to successfully develop and commercialize new products; Allergans ability to conform to regulatory standards and receive requisite regulatory approvals; availability of raw materials and other
key ingredients; uncertainty and costs of legal actions and government investigations; the inherent uncertainty associated with financial projections; fluctuations in Allergans operating results and financial condition, particularly given our manufacturing
and sales of branded products; risks associated with acquisitions, mergers and joint ventures, such as difficulties integrating businesses, uncertainty associated with financial projections, projected synergies, restructuring, increased costs, and adverse
tax consequences; the restructuring completed in connection with Allergans divestiture of its generics business to Teva Pharmaceutical Industries Ltd.; the results of the ongoing business following the completion of the divestiture of Allergans
generics business to Teva; the adverse impact of substantial debt and other financial obligations on the ability to fulfill and/or refinance debt obligations; risks associated with relationships with employees, vendors or key customers as a result of
acquisitions of businesses, technologies or products; our compliance with federal and state healthcare laws, including laws related to fraud, abuse, privacy security and others; generic product competition with our branded products; uncertainty
associated with the development of commercially successful branded pharmaceutical products; costs and efforts to defend or enforce technology rights, patents or other intellectual property; expiration patents on our branded products and the potential
for increased competition from generic manufacturers; competition between branded and generic products; Allergans ability to obtain and afford third-party licenses and proprietary technology we need; Allergans potential infringement of others
proprietary rights; our dependency on third-party service providers and third-party manufacturers and suppliers that in some cases may be the only source of finished products or raw materials that we need; Allergans competition with certain of our
significant customers; the impact of our returns, allowance and chargeback policies on our future revenue; successful compliance with governmental regulations applicable to Allergans and Allergans respective third party providers facilities, products
and/or businesses; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; Allergans vulnerability to and ability to defend against product liability claims and obtain sufficient or
any product liability insurance; Allergans ability to retain qualified employees and key personnel; the effect of intangible assets and resulting impairment testing and impairment charges on our financial condition; Allergans ability to obtain additional
debt or raise additional equity on terms that are favorable to Allergan; difficulties or delays in manufacturing; our ability to manage environmental liabilities; global economic conditions; Allergans ability to continue foreign operations in countries that
have deteriorating political or diplomatic relationships with the United States; Allergans ability to continue to maintain global operations and the exposure to the risks and challenges associated with conducting business internationally; risks associated
with tax liabilities, or changes in U.S. federal or international tax laws to which we are subject, including the risk that the Internal Revenue Service disagrees that Allergan is a foreign corporation for U.S. federal tax purposes; risks of fluctuations in
foreign currency exchange rates; risks associated with cyber-security and vulnerability of our information and employee, customer and business information that Allergan stores digitally; Allergans ability to maintain internal control over financial
reporting; changes in the laws and regulations, affecting among other things, availability, pricing and reimbursement of pharmaceutical products; the highly competitive nature of the pharmaceutical industry; Allergans ability to successfully navigate
consolidation of our distribution network and concentration of our customer base; the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; developments regarding products once they have reached
the market; risks related to Allergans incorporation in Ireland, such as changes in Irish law and such other risks and other uncertainties detailed in Allergans periodic public filings with the Securities and Exchange Commission, including but not limited
to Allergans Annual Report on Form 10-K for the year ended December 31, 2015; and from time to time in Allergans other investor communications. Except as expressly required by law, Allergan disclaims any intent or obligation to update or revise
these forward-looking statements.
NonGAAP Financial Measures
This document contains nonGAAP financial measures. The Appendix hereto presents reconciliations of certain nonGAAP financial measures to the most directly comparable GAAP measures. The nonGAAP measures include non-GAAP net
income, non-GAAP earnings per share, adjusted EBITDA, non-GAAP operating income.
We believe these nonGAAP measures provide useful information to investors because these are among the measures used by our management team to evaluate our operating performance and to make daytoday operating decisions, prepare
internal forecasts, communicate external forward looking guidance to investors, compensate management and allocate the companys resource. We believe this presentation also increases comparability of periodtoperiod results.
Other companies may use similarly titled non GAAP financial measures that are calculated differently from the way we calculate such measures Accordingly our non GAAP financial measures may not be comparable to similar nonmeasures.
Accordingly, non-GAAP measures used by other companies. We caution investors not to place undue reliance on such nonGAAP measures, but instead to consider them with the most directly comparable GAAP measure. NonGAAP financial
measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for our results as reported under GAAP.
AGENDA
1
Q3 2016 Overview
Commercial Highlights
R&D Update
Q3 2016 Financial Results
Q&A
Brent Saunders, CEO & President

Bill Meury, Chief Commercial Officer
David Nicholson, Chief R&D Officer

Tessa Hilado, Chief Financial Officer
BRENT
SAUNDERS
Chairman, CEO and President
ALLERGAN:
A FOCUSED GROWTH
PHARMA LEADER
Category
Leadership
Maintain/achieve # 1 & 2
position in key therapeutic areas
Innovation
driven to address
unmet needs
Operational
Excellence
Strong
Top-Line Growth
Sustainable top line revenue growth
Leading global brands
Targeted geographic expansion
GROWTH
PHARMA
Customer
Intimacy
Deep knowledge of
therapeutic area
environment
Highly
responsive/
service
oriented
Industry leading
operating margins
Sales and marketing engine
Open
Simplified & reliable

Science
manufacturing
R&D
network
Industry leading pipeline to sustain
therapeutic area growth and leadership
Development Powerhouse
SHAREHOLDER FRIENDLY CAPITAL ALLOCATION

DEMONSTRATES STRONG CONVICTION IN OUR FUTURE
Since August 2nd
$5B
Share Repurchase Completed
Announced Today
$10B
> Total Board Authorization

of $15B (additional $5B)
Accelerated Share Repurchase
$0.70
per share
quarterly
dividend
> Expect to Grow Annually

> Maintain Investment
Grade Credit Rating
Stepping Stone Deals

6
Q3 2016 CONTINUING OPERATIONS PERFORMANCE

Operational Excellence
Top-tier revenue growth continues
> Net revenues = $3.6 Billion
+4.5% growth vs prior year

+7.4%* vs prior year excluding FX, Namenda IR,
Divestitures and other adjustments
Top-tier profitability among peer group

continues while making strong investments
in our future
> Gross Margin = 87.8%; Operating Margin = 49.3%
Non-GAAP EPS = $3.32
3
Allergan Q
rd
Report Ca
Promoted wth
o
product gr
ct launch
New produ e
c
performan
brands
Establishedomoted
and non-pr
e
R&D Pipelin
Profitability
All Q3 results in this presentation are for Continuing Operations on a non-GAAP basis.
* Excludes FX, Namenda IR and Divestitures. Excludes the reclassification of revenues of ($23.7) MM in Q3 2016 and ($43.4) MM in Q3 2015 related to the portion of Allergan product
revenues sold by our Anda Distribution Business into discontinued operations. Excludes other adjustments related to an adjustment of $31.7MM recorded in the three months ended
September 30, 2015 related to international other product revenues for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations
during the six months ended June 30, 2015. The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended
September 30, 2015 and had no impact on the nine months ended September 30, 2015.
Continuing operations excludes Anda distribution business as a result of being held for sale on June 30th and closed on October 3rd and the Generics Business sold on August 2nd, 2016
Please refer to the GAAP to non-GAAP tables in the appendix for a reconciliation of our non-GAAP results
KEY PROMOTED BRANDS CONTINUE TO GROW

AT DOUBLE DIGIT RATES
~73% of Q3 revenues growing at double digits on aggregate
Top Global Products and New Launches Represent ~80% of Q3 Revenue
Represent 73% of Q3
Adjusted Revenue
91
15
21
23
13
11
11
68
69
35
50
44
88
-44%
-4%
Excludes FX, Namenda IR and divestitures. Excludes the reclassification of revenues of ($23.7) MM in Q3 2016 and ($43.4) MM in Q3 2015 related to the portion of Allergan product
revenues sold by our Anda Distribution Business into discontinued operations. Excludes other adjustments related to out-of-period adjustments in Q3 2015 net revenues
Viberzi, Vraylar, Kybella and Namzaric
Represents all other product revenues, excluding Namenda IR, divestitures, and reclassification of revenues related to the portion of Allergan product revenues sold
by our Anda Distribution Business into discontinued operations.
All global products revenue metrics excludes the impact of FX
FX
pa
Im
ct
Q
3
Fx
ct
s
O
th
e
rP
ro
du
ol
elz
ic
da
en
am
d-
As
ac
ol/
D
XR
st
ea
Fe
tz
im
a/
Br
Es
tra
ce
rii
ina
/
l
te st
XR
ico
ra rea
er 3
c
l
da
elz
u /B
th s
n
D
S
s
/
O uct
e
/ ma
l
E
e
D
l
m
t
H
A rod
fa tzi
Na
ol
ra Fe
P
ac
Ca ryd/
s
A
ib
Vi
e
c
tra
af
at
e/
Vib
as
in
in
str
ar
By
20
16
4%
li
sto
om
uc
G
la
cz
e
on
trin
c
By
st
oli
ne
dr
Ac
zo
op
ex
d
ur
13%
6%
t/
or
nf an
a
g
i
G
n/ mb
Oz
iga o
m an/C
u
L ag
ph
Al
ex
rd
du
oL
s
oe
O
zu
lo
trin
Lo
ct
s
t
uc
od 2
Pr hes
w c
Ne aun
L
Pr
o
rs
ew
lle
Fi
rs
Fil
le
on
st
ell
/
ss
ze tella
Lin ons
C
s/
C
is
ze
s
is
Re
s
sta
14%
8%
16%
13%
Lin
ox
ot
-32%
21%
es
ta
s
Q
2
Q3 2015
Revenues
($000)
Bo
to
x
20
15
15%
44%
42%
25%
$3,4021
$3,6431
7.4%
32
R&D TEAM CONTINUES TO BUILD & DELIVER THE PIPELINE

Building and delivering a sustainable pipeline through Open Science R&D
Strong R&D productivity

continues YTD:
19
11
Major pharma
and device
approvals
Major
Submissions
7
Major Pipeline
Advancements
9 YTD Stepping Stones

strengthen our pipeline
ANT027
Collaboration
Dermatology
Periocular Ring
technology
Eye Care
Muscarinic agonists neurology
XAF5
Cenicriviroc
Evogliptin
FXR
NASH
NASH
Topical treatment
for Steatoblepharon
RORt
LXR
Dermatology
RST-001
Retinitis Pigmentosa
BRAZIKUMAB
Crohns, Ulcerative colitis

auto-inmune disorders
BILL
MEURY
Chief Commercial Officer
STRONG SALES PERFORMANCE BY THERAPEUTIC AREA

TA
Key Highlights
Q3 Rev
($MM)1
Growth vs PY
(Actual Rates)
Growth vs PY
(Excluding Fx)
EYE CARE
Restasis, Ozurdex strong performance
$903
10%
10%
CNS
Successful Vraylar launch and strong

Botox Tx, offset by Namenda XR decline
$649
2%
3%
AESTHETICS/
DERMATOLOGY
Botox, Fillers continue to drive growth
$756
14%
14%
GI
Linzess and Viberzi key growth

drivers offset by Asacol HD decline
$464
9%
9%
WH
Lo Loestrin remains #1 prescribed OC
$320
15%
15%
UROLOGY
Botox OAB key driver of growth,

strong growth offset by Rapaflo
$89
6%
6%
ANTIINFECTIVE
Growth impacted by Avycaz supply

disruption
$53
<1%
<1%
1. Revenues reflect continuing operations, exclude established brands and divestitures and excludes the reclassification of revenues related to the portion of Allergan
product revenues sold by our Anda Distribution Business into discontinued operations. Botox sales are allocated by indication into Aesthetics, CNS, Urology.
2. Revenues excludes Namenda IR.
11
LINZESS AND VIBERZI: GI FLAGSHIPS

Strong Linzess prescription growth
60,000
Double Digit Growth Continues
55,000
50,000
45,000
40,000
30% prescription
growth in Q3 vs
P/Y
> Linzess uptake in LTC is strong and

continued growth is anticipated
> Launch readiness for Linzess 72 mcg
10
/3
11 0/2
/1 01
11 3/2 5
/2 01
12 7/2 5
/1 01
12 1/2 5
/2 01
5/ 5
2
1/ 01
8 5
1/ /20
22 16
/2
2/ 01
5/ 6
2/ 20
19 16
/2
3/ 01
4/ 6
3/ 20
18 16
/2
4/ 01
1/ 6
4/ 20
15 16
4/ /20
29 16
5/ /20
13 16
5/ /20
27 16
6/ /20
10 16
6/ /20
24 16
/2
7/ 01
8/ 6
7/ 20
22 16
/2
8/ 01
5/ 6
8/ 20
19 16
/2
9/ 01
2/ 6
9/ 20
16 16
9/ /20
3 1
10 0/2 6
/1 01
4/ 6
20
16
35,000
> Majority (73%) of Linzess new

patients are coming from the OTC
market
$3,500,000
Viberzi sales levels at ~90% of Linzess
$3,000,000
$2,000,000
TRxs Continue to Show Strong

Growth Trajectory
$1,500,000
> Use across all severities of IBS-D
$2,500,000
$1,000,000
Linzess total net sale
$500,000
Viberzi total net sale
W
ee
k
W 1
ee
k
W 3
ee
k
W 5
ee
k
W 7
ee
W k9
ee
W k 11
ee
k
W 13
ee
k
W 15
ee
k
W 17
ee
k
W 19
ee
k
W 21
ee
k
W 23
ee
k
W 25
ee
k
W 27
ee
k
W 29
ee
k
W 31
ee
k
W 33
ee
k
W 35
ee
k
W 37
ee
k
W 39
ee
k
W 41
ee
k
W 43
ee
k
45
$0
> OTC conversion increasing

> Broad utilization by primary care
and gastroenterologist
12
MEDICAL AESTHETICS, HIGH QUALITY FAST GROWING

CASH BUSINESS WITH EXCELLENT MARKET DYNAMICS
> Gaining momentum in Stage 2

of launch with DTC launched
in mid-August
2016
2015
% of Patients ages 2030

Years
> Current gender mix is 12% male,

88% female
> JUVDERM VOLBELLA XC launch

October
First and only FDA-approved
filler proven to increase lip fullness
and correct perioral lines for up
to 1 year
Kybella Weekly BD
Treatments
DTC
1,575
n
Fe
b
1M
ar
1Ap
1- r
M
ay
1Ju
n
1Ju
1- l
Au
g
1Se
p
1O
ct
1N
o
1- v
D
ec
4%
VOLBELLA and VOLLURE Launches
Ja
6%
1-
> Millennials use of Botox Cx is

on the rise
1-
> Botox Cx continues to experience

strong growth globally in the quarter
> Male mix for Kybella is 2x higher

than Botox and Juvederm
> JUVDERM VOLLURE XC expected

1H17
Presents a great leap forward as
a Versatile filler
13
EXCELLENT LONG TERM GROWTH PROSPECTS

Penetration rates for Botox in both the aesthetic and
therapeutic markets are still low and have room for growth
Botox Cx
Migraine
OAB
Total Patients
32.4MM
3.28MM
5.5MM
Botox Patients
2.4MM
197K
165K
7%
6%
3%
Penetration Rate
Source: US census data, Allergan market research 2016 and Allergan internal data
14
DEMAND FOR VRAYLAR AND NAMZARIC DRIVING GROWTH

Launch continues
excellent trajectory
33 weeks in the market shows strong TRx

performance
Positive feedback on overall Vraylar profile

continues
Focus as the standard of care

in treatment of moderate AD
P
P
Strong coverage at 85% of Medicare beneficiaries

Full Titration Kit with full launch in Q4
Launch-aligned TRx
6,000
Namzaric New DOT - All Channels

77,000
4,500
New Indication
62,000
3,000
Rexulti
1,500
Latuda
47,000
Vraylar
w
k
w 9
k1
w 1
k1
w 3
k1
w 5
k1
w 7
k1
w 9
k2
w 1
k2
w 3
k2
w 5
k2
w 7
k2
w 9
k3
w 1
k3
w 3
k3
w 5
k3
w 7
k3
w 9
k4
w 1
k4
3
k5
k7
w
k1
k3
w
9/
2
10 5/2
/1 01
6/ 5
11 201
/6 5
11 /20
/2 15
12 7/20
/1 15
8/
2
1/ 01
8/ 5
1/ 20
29 16
2/ /20
19 16
/
3/ 201
11 6
/2
4/ 01
1/ 6
4/ 20
22 16
5/ /20
13 16
/2
6/ 01
3/ 6
6/ 20
24 16
7/ /20
15 16
/2
8/ 01
5/ 6
8/ 20
26 16
9/ /20
16 16
10 /20
/7 16
/2
01
6
32,000
1. Source: IMS Weekly NPA and NTBRx, 23-Sep reporting period. NTBRx data are smoothed by 3-unit boxcar averaging.
15
LAUNCHING TWO NEW DRY EYE PRODUCTS

Dry Eye Market Growing at 15%*
> Broadening our

product offering
to accelerate growth
> Restasis is the market
leader in dry eye
> Maintaining excellent
coverage in both
Commercial Part D
> Preference for

multi-dose bottles
to single unit vials
> Potential to provide

immediate relief by
restoring natural tear film
> FDA approval

Oct 28th
> Appealing alternative to

drop therapy
> Leveraging largest,

strongest and most
experienced sales
force in eye care
> Launch 1Q 2017
* Source: IMS data most recent 4 weeks through 10/21/16 vs same period prior year
16
INTERNATIONAL BUSINESS CONTINUES STRONG

GROWTH AND EXPANSION
WE
+8%
LACAN
Canada & LATAM
+14%
> Eye Care and Aesthetics Driving

International
NESEE
+26%
TMEA
+6%
APAC
+14%
> APAC, Western Europe and

LACAN largest $ growth
contributors
China fastest growing market
(+44%) driven by Aesthetics
> Launches of Constella and
XEN underway and preparing
to launch Truberzi and Belkyra
Regional growth rates in chart reflect Q3 growth vs prior year excluding FX impact
WE: Western Europe
TMEA: Turkey, Middle East and Africa
NESEE: North East and South East Europe
APAC: Asia Pacific
17
FOCUS ON MAXIMIZING ASSETS AND EXECUTING ON FUTURE

LAUNCHES: >10 LAUNCHES UNDERWAY TO DRIVE FUTURE GROWTH
18
DAVID
NICHOLSON
Chief R&D Officer
OPEN SCIENCE IS BUILDING AND DELIVERING

OUR PIPELINE
BUILDING
THE
PIPELINE
OPEN
SCIENCE
>9 stepping stones

additions to the pipeline YTD
DELIVERING
THE
PIPELINE
>19 total major pharma

and device global approvals YTD
>Total of 11 major regulatory
submissions YTD
We identify best-in-class, game

changing, innovative opportunities
within our therapeutic areas by
tapping into the total universe of
sources independent of where
ideas come from
We develop and obtain regulatory

approval for innovative products
through an exceptional team of
scientists, R&D professionals.
20
CONTINUE TO BUILD OUR PIPELINE, 6 NEW STEPPING

STONE ACQUISITIONS SINCE LAST QUARTER
Open Science R&D: We identify the best science regardless of source
TRUE TEAR
TAVILERMIDE
RAPASTINEL
APIMOSTINEL
UBROGEPANT
ATOGEPANT
CGRP antagonists
Periocular Ring
technology
Eye Care
RST-001
Retinitis Pigmentosa
Since Q2 2016
ANT027
Dermatology
XAF5
RUGEN
THERAPEUTICS
Collaboration
Muscarinic agonists
eurology
RELAMORELIN
Topical treatment
for Steatoblepharon
RORt
LXR
Dermatology
Cenicriviroc
Evogliptin
NASH
FXR
NASH
BRAZIKUMAB
Crohns, Ulcerative colitis

auto-inmune disorders
21
DELIVERING ON OUR PIPELINE, ADVANCING MAJOR PROGRAMS

Major
achievements
in our
pipeline
Ubrogepant: Initiated Ph 3 for acute

migraine. Topline results expected 2018.
Atogepant: Initiated Ph 2 for migraine
prophylaxis. Topline results expected 2018.
Rapastinel: Initiated Ph 3 for MDD.
Topline results expected early 2019.
Relamorelin (DG): Positive Ph 2b

study results (option exercised).
Ph 3 to commence 2H 2017.
TRUBERZI (eluxadoline): Positive
Opinion for in EU. Expected launch 2017.
Restasis MD: FDA approval October 28th

SER-120 (nocturia): Favorable vote
from FDA Advisory Committee.
Approval expected 2016
Major
pipeline
catalyst
in the next
12 months
Cariprazine Negative symptoms:

Based on FDA feedback, sNDA filing
expected 1H 2017
Botox Depression: Ph 2 topline results
expected 2H 2017
Semprana (acute migraine): submission
2H 2017
RORt agonist (psoriasis): Ph 2b initiation
1H 2017
Sarecycline (Acne): Ph 3 results
expected early 2017
Cenicriviroc (Nash): Ph 3 initiation 1H

2017
Brazikumab (Crohns): Ph 2a data
1H 2017
True Tear: Potential approval Q1 2017
XEN: Potential approval Q2 2017
Tavilermide: 1st Ph 3 results Q4 2016
Esmya: 2nd Ph 3 results

early 2017
22
Composite Score
RELAMORELIN, POSITIVE RESULTS FROM PHASE 2A /2B

Change from Baseline Mean +/- SE
1
0
-1
-2
FDA Draft Guidance:

Composite endpoints are an acceptable basis for approval
-3
-4
Phase 2b study results
Phase-5 2a study results

-6
Composite1Score
Baseline
Four-Symptom Composite
-1
Week
Placebo (N=36)
RM-131 10 ug BID (N=30)
-2
-3
-4
-5
-6
-7
*p value <0.05 vs. PBO
-8
Baseline
*
2
*
3
Four-symptom composite2: substantial efficacy from baseline

demonstrated by week 12
Change from Baseline ( SE)
Change from Baseline ( SE)
Change from Baseline Mean +/- SE
Four-symptom composite
: change from baseline in
-7
*
1vomiting subgroup
-8
*
*
Four-Symptom Composite
Change from Baseline Pooled Doses
Week
Week
Reduction in vomiting frequency vs baseline at week 4:

Placebo (N=36) 3
RLM (10 ug BID)=-76.8%3; PBO=-12.7%
p-value=0.041
RM-131 10 ug BID (N=30)
Reduction in vomiting frequency vs baseline at week 12:

RLM (10/30/100)=-74.9%4; PBO=-70.5%4 p-value>0.05
FDA Draft Guidance (July 2015) We recommend the use of an endpoint(s) that is based either on: (1) measuring each of the core signs and
symptoms separately, thereby producing individual sign and symptom scores with a responder definition that incorporates each individual sign and
symptom score change; or (2) a summary score of the core signs and symptoms (excluding vomiting) with a responder definition based on meaningful
summary score change and vomiting frequency change.
1. Nausea, abdominal pain, early satiety, bloating. 2. Nausea, abdominal pain, post-prandial fullness, bloating
3. Analysis was done on change from baseline of normalized, weekly vomiting data and reported as percent change, calculated by Motus as 100 x (LS mean change from
baseline/baseline) 4. Analysis was done on change-from-baseline of log-transformed, normalized, weekly vomiting data using a threshold of 4 weekly diary entries and reported, after
being back- transformed, as percent change from baseline
23
TESSA
HILADO
Chief Financial Officer
INITIATING DIVIDEND AND INCREASING SHARE

REPURCHASE TO $15 BILLION
Share
Repurchase
$15 Billion share repurchase authorization

(formerly $10 Billion authorized)
> $5 Billion completed as of October 21st
21 million cumulative shares repurchased at $237.59 average price
> $10 Billion share repurchase to commence in early November under ASR program
Returning
Capital to
Shareholders
> Up to 50% of the ASR program would be hedged through a collar transaction
Forecast 2016 average diluted share count of 408 million
Forecast year end diluted share count of 365 million
Dividend initiation beginning January 1, 2017

Dividend
> Quarterly dividend of $0.70 per share commencing in Q1 2017,

which we expect to grow annually
> Record date February 28, 2017
> Dividend payment date March 28, 2017
25
STRENGTHENING OUR BALANCE SHEET

THROUGH DEBT REPAYMENTS
Capitalization ($ billion)
Debt
Payment
Supports
Investment
Grade Credit
Ratings
Q3 2016
Cash and Marketable Securities
$27.4
Total Debt *
$32.8
Debt to Adjusted EBITDA
4.33 X
Net Debt to Adjusted EBITDA
0.71 X
> Total debt reduction of $9.8B YTD

> $6.5B in contractual maturities over the next 18 months
$2.7B in 2017 and $3.8B in 2018

* Includes $32.75B in Senior Notes and $0.02B in Debt issuance cost, premium and other
26
Q3 2016 FINANCIAL PERFORMANCE

$ millions, except per
share amount (Non
GAAP)*
Q3 2016
Q3 2015
Net Revenue
3,622
3,466
4.5%
Gross Margin %
87.8%
88.7%
386
R&D Expense
SG&A
Y/Y
Q2 2016
Q/Q
3,685
-1.7%
-0.9%
88.0%
-0.2%
305
26.7%
345
12.0%
1,007
867
16.1%
1,039
-3.1%
% of Revenue
27.8%
25.0%
2.8%
28.2%
-0.4%
Operating Income
1,784
1,895
-5.8%
1,860
-4.1%
Op. Margin %
49.3%
54.7%
-5.4%
50.5%
-1.2%
Adjusted EBITDA
1,902
1,987
-4.3%
1,937
-1.8%
Earnings Per
Share
$3.32
$3.41
-2.6%
$3.35
-0.9%
Tax Rate
8.2%
7.7%
0.5%
7.1%
1.1%
(1,092)
1,048
1,383
N/A
Cash Flow From

Ops
N/A
> Revenue growth of 4.5% primarily impacted by Asacol HD

loss of exclusivity, divestitures, lower than expected
Namenda XR and Namenda IR decline
7.4% growth excluding Namenda IR, FX, divestitures

and other adjustments**
> Gross margins remain strong at ~88%
90 points decline versus prior year driven in part
by higher production costs primarily related to capacity

expansion and manufacturing variance
> Operating margin impacted by higher S&M to continue

to support ongoing launches of Vraylar, Viberzi and Kybella
and higher R&D versus prior quarter
> Reported cash flow from operations was ($1.09B)
~$1.72B excluding taxes paid on gain of Gx business
sale, R&D asset acquisitions and restructuring payments
* All metrics are as a % of Net Revenues. Please refer to the GAAP to non-GAAP tables in the appendix for a reconciliation of our non-GAAP results.
** Excludes FX, Namenda IR and Divestitures. Excludes the reclassification of revenues of ($23.7) MM in Q3 2016 and ($43.4) MM in Q3 2015 related to the portion
of Allergan product revenues sold by our Anda Distribution Business into discontinued operations. Excludes other adjustments related to out-of-period adjustments
in Q3 2015 net revenues.
27
US SPECIALIZED THERAPEUTICS Q3 2016 PERFORMANCE

$ millions - (Non GAAP)
Q3 2016
Q3 2015
Y/Y
Q2 2016
Q/Q
> Revenue growth remains strong at 12% vs prior year
Net Revenues
1,453
1,297
12.1%
1,489
-2.4%
Gross Margins
95.2%
94.5%
0.7%
95.0%
0.2%
SG&A
% of Revenue
334
23.0%
253
19.5%
31.6%
3.5%
334
22.4%
-0.1%
0.6%
Med Derm growth strengthened by launch
Segment Margin
72.3%
74.9%
-2.6%
72.5%
-0.2%
Eye Care growth of 13% driven by growth
Medical Aesthetics growth of 14% driven by
Fillers, Botox Cx and recently launched Kybella

of Aczone 7.5%
in Restasis, Ozurdex and Glaucoma drops
Botox Tx had another quarter of double digit

growth at 17% versus prior year
> Sequential 2% revenue decline primarily driven

by seasonality of Medical Aesthetics and Eye Care
> Increase in SG&A versus prior year attributable
to sales force expansions and increased promotion
for key brands including Kybella DTC advertising
Includes revenues earned that were distributed through the Anda Distribution Business to third-party customers.
28
US GENERAL MEDICINE Q3 2016 PERFORMANCE

Q3 2016
Q3 2015
Y/Y
Q2 2016
Q/Q
Net Revenues
1,488
1,552
-4.1%
1,449
2.7%
Gross Margins
85.5%
85.3%
0.2%
85.2%
0.3%
SG&A
% of Revenue
Segment Margin
335
280
19.6%
376
22.5%
18.1%
4.4%
26.0%
-11.0%
-3.5%
63.0%
67.3%
-4.3%
59.2%
3.8%
> Revenue decline of 4% vs prior year primarily

attributed to Asacol HD generic entry, lower
Namenda XR/IR revenues and lower Established
Brands due to Cervidil divestiture and Enablex
generic entry
> Strong growth in Linzess, Lo Loestrin, and other
WH product continued
> New product launches Viberzi and Vraylar
were key contributors to growth
> Increase in SG&A versus prior year primarily
related to higher spending to support launches
of Viberzi and Vraylar
> SG&A declined 11% versus prior quarter due
to timing of promotional spending coupled with
higher prior quarter Vraylar launch expenses
Includes revenues earned that were distributed through the Anda Distribution Business to third-party customers.
29
INTERNATIONAL Q3 2016 PERFORMANCE

Net Revenues
Gross Margins
SG&A
% of Revenue
Segment Margin
Q3 2016
Q3 2015
Y/Y
Q2 2016
Q/Q
698
661
5.6%
757
-7.8%
86.4%
83.6%
2.8%
84.8%
1.6%
216
189
14.3%
238
31.0%
28.6%
2.4%
31.5%
-9.2%
-0.5%
55.4%
55.0%
0.4%
53.4%
2.0%
> Q3 2016 performance growth of 12% vs prior year

excluding FX and an out-of-period adjustment*
> Strong operational revenue growth excluding Fx from
Fillers (+25%), Botox Cx (+18%), Botox Tx (+13%)
and Ozurdex (+29%)
> Sequential Revenue decline driven by seasonality of
Medical Aesthetics and Eye Care primarily in Europe
> APAC, Western Europe and LACAN were the largest
growth contributors versus prior year
> SG&A expenses increased versus prior year in support
of medical aesthetics business and new product
launches (Belkyra, Xen, Earfold and Constella)
* Out-of period adjustment includes an adjustment of $31.7MM recorded in the three months ended September 30, 2015 related to international other product revenues
for the six months ended June 30, 2015 that were reported in discontinued operations instead of continuing operations during the six months ended June 30, 2015.
The impact of this out-of-period adjustment is not material to the six months ended June 30, 2015 or the three months ended September 30, 2015 and had no impact on
the nine months ended September 30, 2015.
30
REVISED GUIDANCE FOR 2016

2016 Guidance (8/8/16)1
Revised 2016 Guidance1
Total Reported Net Revenue2 $14,650$14,900
$14,450$14,650
Gross Margin
~89%
~8788%
Non-GAAP SG&A
~$4 Billion
~$4 Billion
Non-GAAP R&D Spend
~$1.5 Billion
~$1.5 Billion
Tax rate %
~9%
~89%
Non-GAAP Net Interest

Expense/Other
~$1.30 Billion
~$1.25 Billion
Adjusted Diluted EPS
$13.75 - $14.20
$13.30$13.50
Average Share Count
~413 Million
~408 Million*
1. Excludes Anda from Net Revenues and expenses. Guidance based off of Reported Net Revenue
2. Excludes revenues of Allergan products sold through Anda Distribution Business which are no longer included in our reported continuing
operations revenue as a result of discontinued operations accounting.
* For the fourth quarter, forecasted average diluted share count is 383 million.
Above guidance represents non-GAAP figures. Refer to Table 11 of appendix for reconciliation of GAAP to Non-GAAP
31
GROWTH ORIENTED PURE BRANDED COMPANY

WITH LEADING PROFITABILITY
35%
50% 50%
43% 44% 45%
39%
69%
54% 55%
G
IL
D
EL
C
BI
IB
G
N
AM
BV
O
VO
N
PG
AB
SH
PF
E
R
M
BM
26% 28% 28%
AZ
N
LL
Y
AG
N
C
EL
G
G
IL
D
BI
IB
G
N
AM
PG
O
VO
N
SH
AZ
N
BV
22%
AB
PF
E
LL
Y
K
R
M
BM
VS
76% 76%
74% 75%
VS
82%
88% 88%
79%
87% 88%
85%
83% 84%
Operating Margins
96%
AG
N
Gross Margins
P Diverse and sustainable top line growth

P Strong Gross Margins
P Strong Operating Margins
Non-GAAP average year to date. Source: Company filings
* Non-GAAP average year to date excluding Anda Distribution Business
32
ENTERING 2017 STRONG AS A FOCUSED

GROWTH PHARMA LEADER
2016 Events and

Accomplishments
Operational and financial excellence
Strong commercial/financial execution
Capital allocation execution
9 stepping stones transactions through Open Science
Adding innovation in our 7 TAs to meet unmet needs
BOLD employee culture

to drive innovation and
success for the future
Sale of Anda Distribution Business

October 3rd closing
Sale of generics business
August 2nd closing >1yr after announcement
33
APPENDIX
34
Q3 PIPELINE YTD ACCOMPLISHMENTS

APPROVALS
Approvals
Aczone Gel 7.5%
US approved
AESTHETIC
!
Botox ! Volbella !
CFL Japan
lips US
SUBMISSIONS
!
Volite (w/
Voluma ! lidocaine) !
Botox LL Spasticity
US approved
nose EU
WH
CNS
URO, AI,
OTHER
Enzepi EPI
EU
Truberzi
EU (positive opinion)
Namzaric (7/10 and 21/10 doses)

US
Dalvance
single dose
Approved in
US & EU
Teflaro peds
US
Avycaz cIAI
with Ph 3 US
XEN - glaucoma
US (510k)
Linzess 72mcg
sNDA submitted
Liletta single handed inserter

(optimized package)
US Filed
Nebivolol/Valtarsan
US
* Efficacy not demonstrated. Option not exercised.
Liletta single inserter (optimized

package)
US
Voluma XC
Japan
True Tear
US (510k)
Setipiprant - Scalp Hair

growth
Initiation Ph 2a POC 1H
LXR (atopic dermatitis)

Phase 2a results
CE Mark
EYE
CARE
GI
Oxymetazoline (Rosacea)
US NDA submitted
DEVELOPMENT MILESTONES
Saphris Low dose &

Bipolar Mania
US accepted
Ser 120
Nocturia
US accepted
Relamorelin
Phase 2b data
Ulipristal
1st Ph 3 topline results
Rapastinel
Ph 3 initiated
!
!
Cariprazine
aMDD Ph 3 results
Avycaz cUTI
with Phase 3
US
TRV-027*
Ph 2b topline
results
Cariprazine - Bipolar Dep.

Initiated Ph 3
!
Atogepant
!
Initiated Ph 2 US
Ubrogepant
Initiated Ph 3 US
!
35
PIPELINE PRODUCTIVITY CONTINUES

Q4 2016 AND KEY 2017 HIGHLIGHTS
APPROVALS
Approvals
Kybella *
EU 2H
AESTHETIC
EYE
CARE
GI
SUBMISSIONS
Oxymetazoline
Rosacea
Voluma XC
Japan 2H
MDPF Restasis
US 2H
True Tear
Dry Eye
XEN
Glaucoma
DEVELOPMENT MILESTONES
Sarecycline
Acne
Sarecycline
Ph 3 topline results
Botox
Masseter
Ph 2 results
Latanoprost
Entry Ph 3
Botox FHL
US/EU 2H
Voluma Plus
CE Mark 2H
Volbella lips
Japan 2H
Botox CFL
China 2H
Restasis
EU 2H
MDPF Ganfort
EU early 2017
Bimatoprost SR
Ph 3 enrollment
completion
Abicipar
Ph 3enrollment
completion
Brimo DDS
Atrophic AMD. Ph 2
topline results
Omega 3 OTC
Dry Eye
Cortisol Analog
Dry Eye Entry Ph 3
Tavilermide
1st Ph 3
Pilo/Oxy
Presbyopia. Ph 2
topline results
Linzess
Delayed
Release CIC.
Entry Phase 3
Linzess
Low Dose CIC
Ulipristal
Uterine Fibroids
WH
Semprana
Acute
Migraine
US 2H
CNS
URO, AI,
OTHER
Avycaz
cUTI
* Belkyra in International markets (received positive opinion through European Decentralized Procedure).
Botox
MDD
Ph 2
Results
Avastin
Biosimilar
US/EU 2H
2H 2016
2017
Muscarinic
Receptor
Agonist
Entry Ph 1
LiRIS
Interstitial Cystitis.
Entry Phase3
36
Q3 2016 RECONCILIATION TABLES

Table 1:
Allergan plcs statement of operations for the three and nine months ended September 30, 2016 and 2015
Table 2:
Allergan plc's GAAP and Non-GAAP product revenue for Top Global Products for the three months ended
September 30, 2016 and 2015
Table 3:
Allergan plcs Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015
Table 4:
Allergan plcs Condensed Consolidated Statements of Cash Flows for the three and nine months ended
Table 5:
GAAP to non-GAAP statement of operations for the three and nine months ended September 30, 2016 and 2015
Table 6:
Reconciliation of reported net (loss) from continuing operations and diluted earnings per share to non-GAAP
net income and diluted EPS for the three and nine months ended September 30, 2016 and 2015
Table 7:
Reconciliation of reported net (loss) from continuing operations for the three and nine months ended
September 30, 2016 and 2015 to adjusted EBITDA
Table 8:
Net Revenues and contribution margin for US Specialized Therapeutics Business Segment for the three and
nine months ended September 30, 2016 and 2015
Table 9:
Net Revenues and contribution margin for US General Medicine Business Segment for the three and nine months
ended September 30, 2016 and 2015
Table 10: Net Revenues and contribution margin for International Business Segment for the three and nine months ended
Table 11: GAAP to non-GAAP reconciliation of FY 2016 EPS forecast
Table 12: New Segment Legend
37
TABLE 1:ALLERGAN PLCS STATEMENT OF OPERATIONS FOR THE THREE AND NINE MONTHS
ENDED SEPTEMBER 30, 2016 AND 2015
Table 1
ALLERGAN PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in millions, except per share amounts)
Net revenues
Three Months Ended

September 30,
2016
2015
$ 3,622.2
$ 3,469.5
Operating expenses:
Cost of sales (excludes amortization and impairment of
acquired intangibles including product rights)
Research and development
Selling, general and administrative
Amortization
In-process research and development impairments
Asset sales and impairments, net
Total operating expenses
Operating (loss)
Non-operating income (expense):
Interest income
Interest (expense)
Other income (expense), net
Total other income (expense), net
(Loss) before income taxes and noncontrolling interest
(Benefit) for income taxes
Net (loss) from continuing operations, net of tax
Income from discontinued operations, net of tax
Net income
(Income) attributable to noncontrolling interest
Net income attributable to shareholders
Dividends on preferred shares
Net income attributable to ordinary shareholders
(Loss) / income per share attributable to ordinary shareholders - basic:
Continuing operations
Discontinued operations
Net income per share - basic
(Loss) / income per share attributable to ordinary shareholders - diluted:
Continuing operations
Discontinued operations
Net income per share - diluted
Weighted average shares outstanding:
Basic
Diluted
Nine Months Ended

September 30,
2016
2015
$ 10,706.3
$ 9,081.2
462.2
622.8
1,157.2
1,609.1
42.0
(4.7)
3,888.6
(266.4)
710.3
1,260.5
1,022.7
1,557.8
300.0
(4.4)
4,846.9
(1,377.4)
1,381.1
1,662.4
3,463.5
4,831.9
316.9
(24.0)
11,631.8
(925.5)
2,150.0
1,927.9
3,205.2
3,858.9
497.6
3.1
11,642.7
(2,561.5)
18.1
(324.3)
33.6
(272.6)
(539.0)
(158.9)
(380.1)
15,601.9
15,221.8
(1.8)
15,220.0
69.6
$ 15,150.4
3.5
(340.2)
0.2
(336.5)
(1,713.9)
(838.9)
(875.0)
6,177.6
5,302.6
(1.4)
5,301.2
69.6
$ 5,231.6
23.5
(1,002.9)
184.2
(795.2)
(1,720.7)
(825.8)
(894.9)
15,873.2
14,978.3
(4.3)
14,974.0
208.8
$ 14,765.2
7.6
(852.0)
(238.1)
(1,082.5)
(3,644.0)
(1,491.0)
(2,153.0)
6,701.7
4,548.7
(2.6)
4,546.1
162.4
4,383.7
(1.15)
39.73
38.58
(2.40)
15.69
13.29
(2.81)
40.25
37.44
(1.15)
39.73
38.58
(2.40)
15.69
13.29
(2.81)
40.25
37.44
$
$
392.7
392.7
393.6
393.6
394.4
394.4
(6.46)
18.67
12.21
(6.46)
18.67
12.21
358.9
358.9
38
TABLE 2:ALLERGAN PLCS GAAP PRODUCT REVENUE FOR TOP GLOBAL PRODUCTS FOR THE
THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 2
ALLERGAN PLC
NET REVENUES TOP GLOBAL PRODUCTS
(Unaudited; in millions)
Three Months Ended September 30,
U.S.
Global
2016
Botox
Restasis
Fillers
Namenda XR
Lumigan /Ganfort
Bystolic
Linzess /Constella
Alphagan /Combigan
Asacol /Delzicol
Lo Loestrin
Viibryd /Fetzima
Estrace Cream
Minastrin 24
Breast Implants
Carafate / Sulcrate
Ozurdex
Aczone
2015
689.7
$ Change
604.4
% Change
2016
$
2015
496.3
$ Change
435.6
International
% Change
2016
$
2015
193.4
$ Change
85.3
14.1%
60.7
13.9%
371.8
201.8
328.3
167.6
43.5
34.2
13.3%
20.4%
356.4
105.0
312.8
89.7
43.6
15.3
13.9%
17.1%
146.9
214.5
(67.6)
(31.5)%
146.9
214.5
(67.6)
(31.5)%
164.9
157.9
7.0
4.4%
78.3
71.7
6.6
9.2%
86.6
86.2
0.4
0.5%
164.4
155.7
8.7
5.6%
163.9
155.3
8.6
5.5%
0.5
0.4
0.1
25.0%
168.7
118.6
50.1
42.2%
164.4
117.5
46.9
39.9%
4.3
1.1
3.2
134.7
120.8
13.9
11.5%
93.4
81.4
12.0
14.7%
41.3
39.4
1.9
15.4
96.8
168.8
% Change
15.5
77.9
24.6
14.6%
(0.1)
18.9
(0.6)%
24.3%
n.a.
n.m.
4.8%
86.4
157.2
(70.8)
(45.0)%
72.2
141.9
(69.7)
(49.1)%
14.2
15.3
(1.1)
(7.2)%
105.7
90.8
14.9
16.4%
105.7
89.8
15.9
17.7%
1.0
(1.0)
(100.0)%
87.6
84.5
3.1
3.7%
87.6
84.5
3.1
3.7%
n.a.
98.6
87.4
11.2
12.8%
98.6
87.4
11.2
12.8%
n.a.
84.9
86.7
74.4
85.5
10.5
1.2
14.1%
1.4%
84.9
51.1
74.4
50.9
10.5
0.2
14.1%
0.4%
35.6
34.6
1.0
57.0
52.9
4.1
7.8%
56.4
52.9
3.5
6.6%
0.6
0.6
64.3
51.6
12.7
24.6%
20.9
17.6
3.3
18.8%
43.4
34.0
9.4
69.0
48.0
21.0
43.8%
69.0
48.0
21.0
43.8%
(52.0)
2.0
19.7
152.7
(94.7)%
0.2%
(45.4)%
4.4%
(52.0)
22.7
19.7
115.5
(94.7)%
3.4%
(45.4)%
4.1%
Namenda IR
2.9
Other Products Revenues
859.9
Less product sold through our Anda Distribution business(23.7)
Total Net Revenues
$
3,622.2
54.9
857.9
(43.4)
3,469.5
2.9
694.2
(23.7)
2,924.4
54.9
671.5
(43.4)
2,808.9
165.7
697.8
186.4
660.6
(20.7)
37.2
n.a.
2.9%
n.a.
27.6%
n.a.
n.a.
(11.1)%
n.a.
5.6%
39
TABLE 2 (CONT):ALLERGAN PLCS NON-GAAP PRODUCT REVENUE FOR TOP GLOBAL PRODUCTS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Total Revenue Growth
Top Global Products
Q3'16
Total
Botox
Restasis
Namenda IR
Namenda XR
Fillers
Lumigan/Ganfort
Asacol/Delzicol
Bystolic
Alphagan/Combigan
Carafate/Sulcrate
Linzess/Constella
Viibryd/Fetzima
Lo Loestrin
Breast Implants
Estrace Cream
Minastrin 24
Ozurdex
Aczone
Other Product Revenues
Total Revenue
Total Revenue (excluding Namenda IR, divestitures, Anda, Other)
US
Y/Y Growth
(Actual Rates)
Q3'15
Ex-US
Total
US
Y/Y Growth
(ex FX)
Ex-US
689.7
371.8
2.9
146.9
201.8
164.9
86.4
164.4
134.7
57.0
168.7
87.6
105.7
86.7
98.6
84.9
64.3
69.0
836.2
496.3
356.4
2.9
146.9
105.0
78.3
72.2
163.9
93.4
56.4
164.4
87.6
105.7
51.1
98.6
84.9
20.9
69.0
670.5
193.4
15.4
96.8
86.6
14.2
0.5
41.3
0.6
4.3
35.6
43.4
165.7
604.4
328.3
54.9
214.5
167.6
157.9
157.2
155.7
120.8
52.9
118.6
84.5
90.8
85.5
87.4
74.4
51.6
48.0
810.8
435.6
312.8
54.9
214.5
89.7
71.7
141.9
155.3
81.4
52.9
117.5
84.5
89.8
50.9
87.4
74.4
17.6
48.0
624.4
168.8
15.5
77.9
86.2
15.3
0.4
39.4
1.1
1.0
34.6
34.0
186.4
14.1%
13.3%
-94.7%
-31.5%
20.4%
4.4%
-45.0%
5.6%
11.5%
7.8%
42.2%
3.7%
16.4%
1.4%
12.8%
14.1%
24.6%
43.8%
3.1%
14.5%
13.3%
-94.7%
-31.5%
20.9%
5.6%
-44.0%
5.6%
11.8%
7.8%
42.4%
3.7%
16.4%
1.3%
12.8%
14.1%
25.4%
43.8%
3.3%
3,622.2
3,643.0
2,924.4
2,945.2
697.8
697.8
3,465.8
3,401.6
2,805.2
2,772.7
660.6
628.9
4.5%
7.1%
4.8%
7.4%
40
TABLE 3:ALLERGAN PLCS CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER

30, 2016 AND DECEMBER 31, 2015
Table 3
ALLERGAN PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,
2016
Assets
Cash and cash equivalents
Marketable securities
Accounts receivable, net
Inventories
Other current assets
Assets held for sale
Property, plant and equipment, net
Investments and other assets
Product rights and other intangibles, net
Goodwill
Total assets
Liabilities & Equity
Current liabilities
Liabilities held for sale
Current and long-term debt and capital leases
Deferred income taxes and other liabilities
Total equity
Total liabilities and equity
December 31,
2015
7,554.7
19,837.6
2,398.5
705.5
771.7
663.1
1,566.3
461.8
63,022.7
46,625.8
143,607.7
6,210.0
247.5
32,770.0
14,649.8
89,730.4
143,607.7
1,096.0
9.3
2,125.4
757.5
495.3
14,808.9
1,531.3
458.2
67,836.2
46,465.2
135,583.3
4,202.3
2,228.6
42,530.4
10,032.7
76,589.3
135,583.3
41
TABLE 4:ALLERGAN PLCS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 4
ALLERGAN PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
2016
2015
Cash Flows From Operating Activities:
Net income
Reconciliation to net cash provided by operating activities:
Depreciation
Amortization
Provision for inventory reserve
Share-based compensation
Deferred income tax benefit
Pre-tax gain sale of generics business
Non-cash tax effect of gain on sale of generics business
In-process research and development impairments
(Gain) / loss on asset sales and impairments, net
Amortization of inventory step up
Amortization of deferred financing costs
Contingent consideration adjustments, including accretion
Excess tax benefit from stock-based compensation
Other, net
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net
Decrease / (increase) in inventories
Decrease / (increase) in prepaid expenses and other current assets
Increase / (decrease) in accounts payable and accrued expenses
Increase / (decrease) in income and other taxes payable
Increase / (decrease) in other assets and liabilities
Net cash (used in) / provided by operating activities
Cash Flows From Investing Activities:
Additions to property, plant and equipment
Additions to product rights and other intangibles
Sale of generics business
Additions to investments
Proceeds from sale of investments and other assets
Proceeds from sales of property, plant and equipment
Acquisitions of businesses, net of cash acquired
Net cash provided by / (used in) investing activities
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness
Proceeds from borrowings on credit facility and other
Debt issuance and other financing costs
Payments on debt, including capital lease obligations
Proceeds from issuance of preferred shares
Proceeds from issuance of ordinary shares
Proceeds from stock plans
Payments of contingent consideration
Repurchase of ordinary shares
Dividends
Excess tax benefit from stock-based compensation
Net cash (used in) / provided by financing activities
Effect of currency exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental Disclosures of Cash Flow Information
Taxes paid in connection with the sale of the generics business
15,221.8
5,302.6
Nine Months Ended September 30,

2016
2015
$
14,978.3
4,548.7
40.7
1,609.1
45.8
81.1
(190.0)
(24,203.1)
5,749.9
42.0
(4.7)
23.6
15.9
5.3
10.4
51.4
1,593.9
45.2
109.8
(6,882.0)
300.0
(1.2)
313.7
8.7
81.1
(17.7)
(9.4)
117.6
4,836.7
162.7
269.9
(517.1)
(24,203.1)
5,749.9
316.9
(24.0)
42.4
44.6
76.7
(26.6)
(16.0)
183.9
4,192.8
108.6
510.5
(7,470.9)
497.6
57.2
1,019.8
289.2
89.2
(54.0)
54.9
460.8
(38.4)
(86.5)
(92.1)
346.0
(130.0)
(1,092.4)
532.1
(35.3)
(86.4)
(399.2)
112.8
28.1
1,048.2
(40.4)
(221.6)
158.9
331.9
(131.6)
(397.5)
1,508.6
(364.0)
(270.1)
(3.3)
(290.6)
(103.4)
(21.6)
2,974.5
(67.7)
33,304.5
(15,445.5)
14.5
18.8
(74.5)
17,750.1
(102.5)
(62.6)
(6.0)
52.1
(132.8)
(251.8)
(250.5)
33,304.5
(15,445.5)
40.0
33.3
(74.5)
17,607.3
(350.7)
(91.1)
(27.0)
855.8
133.6
(35,242.7)
(34,722.1)
150.0
(6,995.4)
30.7
(13.9)
(2,691.3)
(69.6)
(5.3)
(9,594.8)
2.3
7,065.2
489.5
7,554.7
(230.5)
87.6
(46.3)
(7.2)
(69.7)
17.7
(248.4)
(2.0)
546.0
1,517.9
2,063.9
1,050.0
(10,831.0)
138.0
(77.7)
(2,758.6)
(208.8)
26.6
(12,661.5)
4.3
6,458.7
1,096.0
7,554.7
26,456
2,882.0
(310.8)
(4,326.7)
4,929.7
4,071.1
195.8
(138.3)
(108.2)
(138.4)
54.0
33,566.6
(5.1)
1,813.9
250.0
2,063.9
2,571.7
2,571.7
42
TABLE 5: GAAP TO NON-GAAP STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED
SEPTEMBER 30, 2016 AND 2015
Table 5
ALLERGAN PLC
GAAP TO NON-GAAP ADJUSTMENTS
GAAP
Expenditures incurred with the Pfizer transaction
Purchase accounting impact on stock-based compensation
for acquired awards
Severance due to integration of acquired entities and other
restructuring programs
Integration charges of acquired businesses
Brand related milestones and upfront expenses for asset
acquisitions
Retrosense
Arkana
Merck license agreement
Accretion and fair-value adjustments to contingent
consideration
Mark-to-market adjustments for foreign currency option
contracts
Non-cash amortization of debt premium recognized in
purchase accounting
Abandonment of certain R&D projects acquired in the
Forest acquisition
Asset sales and impairments, other
Litigation settlement related charges
Other adjustments
Income taxes on pre-tax adjustments
Non-GAAP Adjusted
Research &
Development
$
622.8
(1.3)
(2.2)
(5.2)
(9.3)
(1.7)
(8.0)
(16.3)
(12.0)
(0.3)
(6.4)
(4.1)
(2.9)
(2.6)
3.7
(12.4)
(38.5)
(59.7)
(48.2)
(100.0)
(10.4)
Discrete income tax events
(5.5)
0.1
-
(5.8)
-
Three Months Ended September 30, 2016

Selling &
General &
Asset sales and Interest expense,
Other income
Marketing
Administrative
Amortization
Impairments, net
net
(expense)
$
796.0 $
361.2 $
1,609.1 $
37.3 $
(306.2) $
33.6
COGS
462.2
Net Revenue
$
3,622.2
3,622.2
442.2
386.4
(18.2)
(40.8)
1.3
-
(10.3)
(42.0)
4.7
-
147.7
33.6
Three Months Ended September 30, 2015

Selling &
General &
Other income
Marketing
Administrative
Amortization
Impairments, net
net
(expense)
683.6 $
339.1 $
1,557.8 $
295.6 $
(336.7) $
0.2
231.3
(316.5) $
775.6
Income taxes
(158.9)
(1,609.1)
-
134.5
123.3
ALLERGAN PLC
GAAP
Impact of selling through purchase accounting mark-up on

acquired inventory
for acquired awards
acquisitions
Naurex
Darpin
Other
consideration
contracts
purchase accounting
Allergan acquisition
Other adjustments
Non-GAAP Adjusted
Net Revenue
3,469.5
COGS
710.3
Research &
Development
1,260.5
(292.9)
(4.3)
(15.4)
(24.6)
(18.6)
(0.2)
(0.2)
(3.2)
(19.5)
(7.3)
3.6
(7.1)
(80.5)
(571.7)
(35.0)
(250.0)
(0.6)
(20.6)
(60.1)
Income taxes
(838.9)
(0.6)
(4.5)
(3.7)
-
1.7
-
3,465.8
392.1
305.0
657.0
(17.5)
$
210.3
(1,557.8)
$
(19.4)
(300.0)
4.4
$
(356.1) $
(5.0)
-
513.7
443.0
(4.8) $
117.8
43
TABLE 5 (CONT): GAAP TO NON-GAAP STATEMENT OF OPERATIONS FOR THE NINE MONTHS
ENDED SEPTEMBER 30, 2016 AND 2015
ALLERGAN PLC
GAAP

acquired inventory
Expenditures incurred with the Pfizer transaction
for acquired awards
acquisitions
Topokine
Anterios
Retrosense
Arkana
Heptares
Other adjustments
consideration
contracts
purchase accounting
Women's helathcare portfolio product impairment
Forest acquisition
Other adjustments
COGS
1,381.1
Research &
Development
1,662.4
Selling &
Marketing
2,429.6
Nine Months Ended September 30, 2016

General &
Other income
Administrative
Amortization
Impairments, net
net
(expense)
$
1,033.9 $
4,831.9 $
292.9 $
(979.4) $
184.2
(42.4)
(3.5)
(5.7)
(26.2)
(57.5)
(6.4)
(31.8)
(55.3)
(35.7)
(3.6)
(8.9)
(6.7)
3.4
(8.0)
(3.7)
(17.8)
(121.5)
(85.8)
(89.2)
(59.7)
(48.2)
(100.0)
(125.0)
(34.2)
(13.4)
(65.8)
(150.0)
Income taxes
(825.8)
(0.1)
(18.4)
(24.0)
(189.9)
(5.8)
-
(0.1)
-
(42.0)
(37.0)
-

Non-GAAP Adjusted
Net Revenue
10,706.3
10,706.3
1,302.9
1,007.9
(100.0)
(4.5)
-
(4,831.9)
-
2,336.3
678.4
(40.6)
-
(1,020.0) $
34.2
1,127.8
62.2
$
364.2
ALLERGAN PLC
GAAP

acquired inventory
Unsalable inventory resulting from the sale of the
Company's Respiratory Business
for acquired awards
acquisitions
Naurex
Darpin
Other
consideration
contracts
purchase accounting
Amortization of bridge loan commitment fees
Women's healthcare portfolio product impairment
Interest rate lock impact
Other adjustments
Non-GAAP Adjusted
Net Revenue
9,081.2
COGS
2,150.0
Research &
Development
1,927.9
Selling &
Marketing
2,017.2
Nine Months Ended September 30, 2015

General &
Other income
Administrative
Amortization
Impairments, net
net
(expense)
Income taxes
$
1,188.0 $
3,858.9 $
500.7 $
(844.4) $
(238.1) $
(1,491.0)
(977.7)
(35.3)
(19.2)
(119.0)
(100.2)
(262.1)
(11.5)
(2.0)
(75.3)
(23.2)
(79.6)
(0.5)
(124.7)
(241.0)
(571.7)
(50.0)
(250.0)
(25.6)
(53.1)
(34.7)
(3.8)
-
0.3
-
1.7
-
9,077.4
1,051.2
778.7
1,838.6
0.5
(42.2)
-
488.4
(192.1)
(3,858.9)
$
(20.5)
(9.6)
$
(50.8)
-
(300.0)
(8.6)
$
(895.2) $
263.0
(31.0)
2.3
(3.8) $
1,350.3
450.0
309.3
44
TABLE 6: RECONCILIATION OF REPORTED NET (LOSS) FROM CONTINUING OPERATIONS AND

DILUTED EARNINGS PER SHARE TO NON-GAAP NET INCOME AND DILUTED EPS FOR THE THREE
AND NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 6
ALLERGAN PLC
RECONCILIATION TABLE
(Unaudited; in millions except per share amounts)
Three Months Ended
September 30,
2016
2015
Nine Months Ended

September 30,
2016
2015
GAAP to Non-GAAP Adjusted net income calculation

GAAP (loss) from continuing operations attributable to shareholders
Adjusted for:
Amortization
(1)
Acquisition and licensing charges
Accretion and fair-value adjustments to contingent consideration
Impairment/asset sales and related costs
Non-recurring (gain) / losses
Legal settlements
Income taxes on items above and other income tax adjustments
Non-GAAP adjusted net income attributable to
shareholders
(381.9)
$ (876.4)
1,609.1
321.5
15.9
37.3
18.2
40.8
(282.2)
1,557.8
1,297.7
81.3
295.6
4.5
17.5
(956.7)
(899.2)
$ (2,155.6)
4,831.9
793.2
79.3
292.9
18.4
100.0
(1,190.0)
3,858.9
3,155.9
87.3
500.7
42.2
20.5
(1,800.3)
$ 1,378.7
$ 1,421.3
4,026.5
3,709.6
Diluted (loss) per share from continuing operations attributable to shareholders- GAAP
(0.97)
(2.23)
(2.28)
(6.01)
Non-GAAP adjusted diluted net income per share attributable to shareholders
3.32
3.41
9.66
9.82
Diluted earnings per share
Basic weighted average ordinary shares outstanding

Effect of dilutive securities:
Dilutive shares
Diluted weighted average ordinary shares outstanding
(1)
392.7
393.6
394.4
358.9
22.0
414.7
22.7
416.3
22.3
416.7
18.8
377.7
Includes stock-based compensation due to the Allergan, Forest and Warner Chilcott acquisitions as well as the valuation accounting impact in interest expense, net.
45
TABLE 7: RECONCILIATION OF REPORTED NET (LOSS) FROM CONTINUING OPERATIONS FOR

THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015 TO ADJUSTED EBITDA
Table 7
ALLERGAN PLC
ADJUSTED EBITDA and ADJUSTED OPERATING INCOME, RECONCILIATION TABLE
Three Months Ended

September 30,
2016
2015

Plus:
Interest expense
Interest income
(Benefit) for income taxes
Depreciation (includes accelerated depreciation)
Amortization
EBITDA
Adjusted for:
Acquisition and licensing and other charges
Legal settlements
Share-based compensation
Adjusted EBITDA
Adjusted for:
Depreciation
Dividend income
Share-based compensation restructuring charges and purchase
accounting impact on stock-based compensation for acquired awards
Adjusted Operating Income
(381.9)
324.3
(18.1)
(158.9)
40.7
1,609.1
1,415.2
293.8
37.3
18.2
40.8
15.9
81.0
1,902.2
(876.4)
340.2
(3.5)
(838.9)
37.9
1,557.8
217.1
1,254.2
295.6
4.5
17.5
81.3
117.0
1,987.2
Nine Months Ended

September 30,
2016
2015
(899.2)
1,002.9
(23.5)
(825.8)
114.5
4,831.9
4,200.8
704.6
292.9
18.4
100.0
79.3
257.0
5,653.0
(2,155.6)
852.0
(7.6)
(1,491.0)
96.0
3,858.9
1,152.7
2,706.2
500.7
42.2
20.5
87.3
625.3
5,134.9
(40.7)
(34.1)
(37.9)
-
(114.5)
(34.1)
(96.0)
-
(43.0)
(54.1)
(127.8)
(124.8)
1,784.4
1,895.2
5,376.6
4,914.1
46
TABLE 8: NET REVENUES AND CONTRIBUTION MARGIN FOR US SPECIALIZED THERAPEUTICS

BUSINESS SEGMENT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 8
ALLERGAN PLC
US Specialized Therapeutics Product Revenue
Change

2016
$
Total Eye Care
Restasis
Lumigan /Ganfort
Alphagan /Combigan
Ozurdex
Eye Drops
Other Eye Care
Total Medical Aesthetics
Facial Aesthetics
Botox Cosmetics
Fillers
Kybella
Plastic Surgery
Breast Implants
Other Plastic Surgery
Skin Care
SkinMedica
Latisse
Total Medical Dermatology
Aczone
Tazorac
Botox Hyperhidrosis
Other Medical Dermatology
Total Neuroscience & Urology
Botox Therapeutics
Rapaflo
Other Revenues
Net revenues
(1)
608.5
356.4
78.3
93.4
20.9
50.2
9.3
388.9
293.7
174.5
105.0
14.2
52.2
51.1
1.1
43.0
25.8
17.2
116.1
69.0
27.5
16.3
3.3
330.7
305.5
25.2
9.0
1,453.2
2015
$
(1) Includes revenues earned that were distributed through the Anda Distribution business to third party customers.
(1)
539.9
312.8
71.7
81.4
17.6
45.3
11.1
340.1
249.0
159.3
89.7
54.3
50.9
3.4
36.8
23.0
13.8
107.8
48.0
27.6
15.0
17.2
291.4
261.3
30.1
17.4
1,296.6
Dollars
$
68.6
43.6
6.6
12.0
3.3
4.9
(1.8)
48.8
44.7
15.2
15.3
14.2
(2.1)
0.2
(2.3)
6.2
2.8
3.4
8.3
21.0
(0.1)
1.3
(13.9)
39.3
44.2
(4.9)
(8.4)
156.6
%
12.7%
13.9%
9.2%
14.7%
18.8%
10.8%
(16.2)%
14.3%
18.0%
9.5%
17.1%
n.a.
(3.9)%
0.4%
(67.6)%
16.8%
12.2%
24.6%
7.7%
43.8%
(0.4)%
8.7%
(80.8)%
13.5%
16.9%
(16.3)%
(48.3)%
12.1%
47
TABLE 8 (CONT): NET REVENUES AND CONTRIBUTION MARGIN FOR US SPECIALIZED

THERAPEUTICS BUSINESS SEGMENT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016 AND
2015
Change

2016
$
Total Eye Care
Restasis
Lumigan /Ganfort
Alphagan /Combigan
Ozurdex
Eye Drops
Other Eye Care
Facial Aesthetics
Botox Cosmetics
Fillers
Kybella
Plastic Surgery
Breast Implants
Other Plastic Surgery
Skin Care
SkinMedica
Latisse
Total Medical Dermatology
Aczone
Tazorac
Botox Hyperhidrosis
Other Medical Dermatology
Total Neuroscience & Urology
Botox Therapeutics
Rapaflo
Other Neuroscience & Urology
Other Revenues
Net revenues
(1)
1,777.6
1,026.4
240.4
274.3
61.8
140.1
34.6
1,182.6
893.3
529.8
325.3
38.2
153.1
149.2
3.9
136.2
81.5
54.7
282.2
156.1
68.0
48.9
9.2
963.8
875.3
87.6
0.9
34.6
4,240.8
2015
$
(1)
1,213.2
651.4
165.9
184.9
36.9
131.8
42.3
761.4
547.9
341.2
206.7
122.5
112.8
9.7
91.0
51.6
39.4
249.4
114.3
65.7
35.5
33.9
637.2
549.7
87.5
28.4
2,889.6
Dollars
$
564.4
375.0
74.5
89.4
24.9
8.3
(7.7)
421.2
345.4
188.6
118.6
38.2
30.6
36.4
(5.8)
45.2
29.9
15.3
32.8
41.8
2.3
13.4
(24.7)
326.6
325.6
0.1
0.9
6.2
1,351.2
%
46.5%
57.6%
44.9%
48.4%
67.5%
6.3%
(18.2)%
55.3%
63.0%
55.3%
57.4%
n.a.
25.0%
32.3%
(59.8)%
49.7%
57.9%
38.8%
13.2%
36.6%
3.5%
37.7%
(72.9)%
51.3%
59.2%
0.1%
n.a.
21.8%
46.8%
48
TABLE 9: NET REVENUES AND CONTRIBUTION MARGIN FOR US GENERAL MEDICINE BUSINESS
SEGMENT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 9
ALLERGAN PLC
US General Medicine Product Revenue
Change

2016
Total Central Nervous System (CNS)
Namenda XR
Namzaric
Viibryd /Fetzima
Vraylar
Saphris
Namenda IR
Total Gastrointestinal (GI)
Linzess
Viberzi
Asacol /Delzicol
Carafate /Sulcrate
Canasa /Salofalk
Zenpep
Other GI
Total Women's Health
Lo Loestrin
Minastrin 24
Estrace Cream
Liletta
Other Women's Health
Total Anti-Infectives
Teflaro
Avycaz
Dalvance
Other Anti-Infectives
Established Brands
Bystolic
Armour Thyroid
Enablex
Lexapro
Savella
PacPharma
Other Established Brands
Other Revenues
Net revenues
(1)
325.5
146.9
14.9
87.6
32.4
40.8
2.9
431.4
164.4
30.9
72.2
56.4
47.2
52.5
7.8
305.3
105.7
84.9
98.6
4.4
11.7
52.5
33.3
4.8
10.3
4.1
319.3
163.9
39.1
1.9
15.6
28.1
6.2
64.5
54.1
1,488.1
2015
$
(1)
406.7
214.5
1.7
84.5
51.1
54.9
398.6
117.5
141.9
52.9
34.6
43.1
8.6
268.0
89.8
74.4
87.4
5.8
10.6
52.3
35.8
7.5
4.9
4.1
400.5
155.3
34.7
17.2
17.8
29.0
27.4
119.1
25.9
1,552.0
Dollars
(81.2)
(67.6)
13.2
3.1
32.4
(10.3)
(52.0)
32.8
46.9
30.9
(69.7)
3.5
12.6
9.4
(0.8)
37.3
15.9
10.5
11.2
(1.4)
1.1
0.2
(2.5)
(2.7)
5.4
(81.2)
8.6
4.4
(15.3)
(2.2)
(0.9)
(21.2)
(54.6)
28.2
(63.9)
%
(20.0)%
(31.5)%
n.m.
3.7%
n.a.
(20.2)%
(94.7)%
8.2%
39.9%
n.a.
(49.1)%
6.6%
36.4%
21.8%
(9.3)%
13.9%
17.7%
14.1%
12.8%
(24.1)%
10.4%
0.4%
(7.0)%
(36.0)%
110.2%
0.0%
(20.3)%
5.5%
12.7%
(89.0)%
(12.4)%
(3.1)%
(77.4)%
(45.8)%
108.9%
(4.1)%
49
TABLE 9 (CONT): NET REVENUES AND CONTRIBUTION MARGIN FOR US GENERAL MEDICINE
BUSINESS SEGMENT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Change

2016
Total Central Nervous System (CNS)
Namenda XR
Namzaric
Viibryd /Fetzima
Vraylar
Saphris
Namenda IR
Total Gastrointestinal (GI)
Linzess
Viberzi
Asacol /Delzicol
Carafate /Sulcrate
Canasa /Salofalk
Zenpep
Other GI
Total Women's Health
Lo Loestrin
Minastrin 24
Estrace Cream
Liletta
Other Women's Health
Total Anti-Infectives
Teflaro
Avycaz
Dalvance
Other Anti-Infectives
Established Brands
Bystolic
Armour Thyroid
Enablex
Lexapro
Savella
PacPharma
Other Established Brands
Other Revenues
Net revenues
(1)
964.6
486.5
38.0
252.6
51.1
123.6
12.8
1,277.0
452.0
55.3
297.9
167.7
135.0
145.1
24.0
865.1
296.0
247.5
276.4
15.0
30.2
167.1
101.9
26.9
26.7
11.6
1,038.8
477.8
121.8
14.7
50.8
74.1
49.7
249.9
78.3
4,390.9
2015
$
(1)
1,485.1
569.8
3.3
244.8
134.3
532.9
1,138.4
325.1
407.8
153.4
102.2
121.5
28.4
716.7
251.7
195.3
229.4
10.7
29.6
138.3
105.3
12.9
11.3
8.8
1,267.7
476.1
88.9
51.5
53.6
80.6
56.6
460.4
57.5
4,803.7
Dollars
(520.5)
(83.3)
34.7
7.8
51.1
(10.7)
(520.1)
138.6
126.9
55.3
(109.9)
14.3
32.8
23.6
(4.4)
148.4
44.3
52.2
47.0
4.3
0.6
28.8
(3.4)
14.0
15.4
2.8
(228.9)
1.7
32.9
(36.8)
(2.8)
(6.5)
(6.9)
(210.5)
20.8
(412.8)
%
(35.0)%
(14.6)%
n.m.
3.2%
n.a.
(8.0)%
(97.6)%
12.2%
39.0%
n.a.
(26.9)%
9.3%
32.1%
19.4%
(15.5)%
20.7%
17.6%
26.7%
20.5%
40.2%
2.0%
20.8%
(3.2)%
108.5%
136.3%
31.8%
(18.1)%
0.4%
37.0%
(71.5)%
(5.2)%
(8.1)%
(12.2)%
(45.7)%
36.2%
(8.6)%
50
TABLE 10: NET REVENUES AND CONTRIBUTION MARGIN FOR INTERNATIONAL BUSINESS
SEGMENT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
Table 10
ALLERGAN PLC
International Product Revenue
Change

2016
2015
$
Total Eye Care
Lumigan /Ganfort
Alphagan /Combigan
Ozurdex
Optive
Other Eye Drops
Restasis
Other Eye Care
Facial Aesthetics
Botox Cosmetics
Fillers
Belkyra (Kybella )
Plastic Surgery
Breast Implants
Earfold
Skin Care
Botox Therapeutics and Other
Botox Therapeutics
Asacol /Delzicol
Constella
Other Products**
Other Revenues
Net revenues**
294.2
86.6
41.3
43.4
25.6
42.1
15.4
39.8
251.0
212.6
115.3
96.8
0.5
35.8
35.6
0.2
2.6
134.6
78.1
14.2
4.3
38.0
18.0
697.8
281.5
86.2
39.4
34.0
23.2
44.0
15.5
39.2
214.8
176.5
98.6
77.9
34.6
34.6
3.7
155.5
70.2
15.3
1.1
68.9
8.8
660.6
Dollars
$
12.7
0.4
1.9
9.4
2.4
(1.9)
(0.1)
0.6
36.2
36.1
16.7
18.9
0.5
1.2
1.0
0.2
(1.1)
(20.9)
7.9
(1.1)
3.2
(30.9)
9.2
37.2
%
4.5%
0.5%
4.8%
27.6%
10.3%
(4.3)%
(0.6)%
1.5%
16.9%
20.5%
16.9%
24.3%
n.a.
3.5%
2.9%
n.a.
(29.7)%
(13.4)%
11.3%
(7.2)%
n.m.
(44.8)%
104.5%
5.6%
** Includes an adjustment of $31.7 million recorded in the three months ended September 30, 2015
related to international other product revenues for the six months ended June 30, 2015 that were
reported in discontinued operations instead of continuing operations during the six months ended
June 30, 2015. The impact of this out-of-period adjustment is not material to the six months
ended June 30, 2015 or the three months ended September 30, 2015 and had no impact on the
nine months ended September 30, 2015. Excluding this adjustment, international revenues would
have increased 12% on a performance basis.
51
TABLE 10 (CONT): NET REVENUES AND CONTRIBUTION MARGIN FOR INTERNATIONAL

BUSINESS SEGMENT FOR THE NINE MONTHS ENDED JUNE 30, 2016 AND 2015
Change

2016
2015
$
Total Eye Care
Lumigan /Ganfort
Alphagan /Combigan
Ozurdex
Optive
Other Eye Drops
Restasis
Other Eye Care
Facial Aesthetics
Botox Cosmetics
Fillers
Belkyra (Kybella )
Plastic Surgery
Breast Implants
Earfold
Skin Care
Botox Therapeutics and Other
Botox Therapeutics
Asacol /Delzicol
Constella
Other Products
Other Revenues
Net revenues
904.4
269.2
127.3
130.2
75.7
131.2
49.7
121.1
780.0
658.7
352.9
304.2
1.6
112.9
112.5
0.4
8.4
399.0
240.0
40.5
12.7
105.8
44.7
2,128.1
623.7
189.7
87.4
72.7
51.9
99.5
31.8
90.7
509.9
416.4
234.9
181.5
85.6
85.6
7.9
321.5
158.5
47.8
2.9
112.3
41.3
1,496.4
Dollars
$
280.7
79.5
39.9
57.5
23.8
31.7
17.9
30.4
270.1
242.3
118.0
122.7
1.6
27.3
26.9
0.4
0.5
77.5
81.5
(7.3)
9.8
(6.5)
3.4
631.7
%
45.0%
41.9%
45.7%
79.1%
45.9%
31.9%
56.3%
33.5%
53.0%
58.2%
50.2%
67.6%
n.a.
31.9%
31.4%
n.a.
6.3%
24.1%
51.4%
(15.3)%
n.m.
(5.8)%
8.2%
42.2%
52
TABLE 11: GAAP TO NON-GAAP RECONCILIATION OF FY 2016 EPS FORECAST
$ in millions
Adjusted for:
Amortization
LOW
HIGH
$ (1,225.0)
$ (1,150.0)
(1)
Acquisition and licensing charges

Legal settlements
Income taxes on items above and other income tax adjustments
Non-GAAP Adjusted net income attributable to
shareholders
6,440.0
6,440.0
1,175.0
85.0
292.9
18.4
100.0
1,225.0
95.0
292.9
18.4
100.0
(1,461.3)
(1,511.3)
$ 5,425.0
$ 5,510.0
Diluted (loss) per share from continuing operations attributable to shareholders- GAAP
(3.17)
(2.98)
Non-GAAP Adjusted diluted net income per share attributable to shareholders
13.30
13.50
Diluted earnings per share
Basic weighted average ordinary shares outstanding

Effect of dilutive securities:
Dilutive shares
386.0
386.0
22.0
22.0
Diluted weighted average ordinary shares outstanding
408.0
408.0
53
TABLE 12: NEW SEGMENT LEGEND

US General Medicine
US Specialized Therapeutics
Restasis
Lumigan/Ganfort
Eye Care
AlphaganCombigan
Ozurdex
Eye Drops
Other Eye Care

(includes):
Relestat/Elestat
Trivaris
Acular/Acuvail
Zymar/Zymaxid
Ocuflox
Z-Pred
Lastacaft
Other
CNS
Breast implants
GastroIntestinal
Med
Dermatology
Neuroscience
& Urology
Tazorac
Botox
Hyperhidrosis
Other Derm
(include): Cordran
tape/others
Botox Therapeutic
Rapaflo
AlphaganCombigan
Zenpep
Ozurdex
Optive
Asacol/Delzicol
Restasis
Other GI (includes):
Pylera
Viokace
Reactiv
Other Eye drops
Other Eye
care
(includes):
Elestat
Trivaris
Acular
Acuvail
Zymar
Zymaxid
Ocuflox
Z-Pred
Lastacaft
Other
Canasa/Salofalk
Facial Aesthetics
Other: SeriScaffold
Aczone
Saphris
Carafate/Sulcrate
Womens
Health
Latisse
Namzaric
Viberzi
Skin Care
SkinMedica
Lumigan/Ganfort
Linzess
Fillers
Plastic Surgery
Vraylar
Eye Care
Kybella
Medical
Aesthetics
Namenda XR/IR
Viibryd/Fetzima
Facial Aesthetics
Botox Cosmetic
International
AntiInfectives
Lo Loestrin
Liletta
Minastrin 24
Estrace Cream
Other WH (includes)
Crinone
Nuvessa
Teflaro
Dalvance
Avycaz
Other AI (includes):
Monurol
Bystolic
Savella
Armour Thyroid
Established
Brands/All
Other
Enablex
Lexapro
PacPharma
Other Established
Brands : Actonel,
Aerochamber,
Androderm, Bentyl,
Celexa, Femring,
Fioricet, Generess,
Infed, Kadian Norco,
Morphine, Other
Botox Cosmetic
Belkyra (Kybella)
Medical
Aesthetics
Fillers
Plastic Surgery
Breast
implants
Other
Skin Care
Botox Therapeutics
Other
Therapeutics
Asacol/Delzicol
Constella
Others include: Rapaflo,
Macrobid, other
54

Allergan Q3 Earnings Deck

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Allergan Q3 Earnings Deck

Uploaded by

Copyright:

Available Formats

Q3 2016

ALLERGAN CAUTIONARY STATEMENT REGARDING

Q3 2016 Financial Results

Brent Saunders, CEO & President

David Nicholson, Chief R&D Officer

Simplified & reliable

SHAREHOLDER FRIENDLY CAPITAL ALLOCATION

> Total Board Authorization

Accelerated Share Repurchase

> Expect to Grow Annually

Stepping Stone Deals

Q3 2016 CONTINUING OPERATIONS PERFORMANCE

+4.5% growth vs prior year

Top-tier profitability among peer group

Non-GAAP EPS = $3.32

KEY PROMOTED BRANDS CONTINUE TO GROW

Viberzi, Vraylar, Kybella and Namzaric

All global products revenue metrics excludes the impact of FX

R&D TEAM CONTINUES TO BUILD & DELIVER THE PIPELINE

Strong R&D productivity

9 YTD Stepping Stones

Muscarinic agonists neurology

Crohns, Ulcerative colitis

STRONG SALES PERFORMANCE BY THERAPEUTIC AREA

Restasis, Ozurdex strong performance

Successful Vraylar launch and strong

Botox, Fillers continue to drive growth

Linzess and Viberzi key growth

Lo Loestrin remains #1 prescribed OC

Botox OAB key driver of growth,

Growth impacted by Avycaz supply

LINZESS AND VIBERZI: GI FLAGSHIPS

Double Digit Growth Continues

> Linzess uptake in LTC is strong and

> Majority (73%) of Linzess new

Viberzi sales levels at ~90% of Linzess

TRxs Continue to Show Strong

> Use across all severities of IBS-D

Linzess total net sale

Viberzi total net sale

> OTC conversion increasing

MEDICAL AESTHETICS, HIGH QUALITY FAST GROWING

> Gaining momentum in Stage 2

% of Patients ages 2030

> Current gender mix is 12% male,

> JUVDERM VOLBELLA XC launch

VOLBELLA and VOLLURE Launches

> Millennials use of Botox Cx is

> Botox Cx continues to experience

> Male mix for Kybella is 2x higher

> JUVDERM VOLLURE XC expected

EXCELLENT LONG TERM GROWTH PROSPECTS

DEMAND FOR VRAYLAR AND NAMZARIC DRIVING GROWTH

33 weeks in the market shows strong TRx

Positive feedback on overall Vraylar profile

Focus as the standard of care

Strong coverage at 85% of Medicare beneficiaries

Namzaric New DOT - All Channels

LAUNCHING TWO NEW DRY EYE PRODUCTS

> Broadening our

> Preference for

> Potential to provide

> FDA approval

> Appealing alternative to